Etoricoxib

Generic Name: Etoricoxib

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₅ClN_₂O_₂S

CAS Number: 202409-33-4

Unique Ingredient Identifier: WRX4NFY03R

Background: Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.

Indication: For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.

Associated Conditions: Ankylosing Spondylitis (AS), Gout, Osteoarthritis (OA), Rheumatoid Arthritis, Moderate Pain

Clinical Trials

Comparison of the Anti-Inflammatory Efficacy of Preemptive Dexamethasone and Etoricoxib

Early Phase 1

Conditions: Effect of Drug

Interventions: Drug: Dexamethasone
Drug: Etoricoxib 60 mg

First Posted Date: 2021-12-02

Last Posted Date: 2021-12-16

Lead Sponsor: Dow University of Health Sciences

Target Recruit Count: 170

Registration Number: NCT05142098

Efficacy and Safety of Fixed-dose Combination of Etoricoxib/Tramadol vs Acetaminophen/Tramadol for Acute Low Back Pain

Phase 3

Completed

Conditions: Acute Low Back Pain

Interventions: Drug: Acetaminophen 325 mg / Tramadol 37.5 mg
Drug: Etoricoxib 90 mg / Tramadol 50 mg

First Posted Date: 2021-07-20

Last Posted Date: 2022-04-13

Lead Sponsor: Laboratorios Silanes S.A. de C.V.

Target Recruit Count: 124

Registration Number: NCT04968158

Locations: 🇲🇽
Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico

Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting Conditions

Phase 1

Conditions: Bioequivalence

Interventions: Drug: Etoricoxib film-coated tablet 120 mg
Drug: Arcoxia® film-coated tablet 120 mg

First Posted Date: 2021-04-05

Last Posted Date: 2021-04-05

Lead Sponsor: Pharmtechnology LLC

Target Recruit Count: 34

Registration Number: NCT04830579

Locations: 🇷🇺
Private healthcare institution "Clinical Hospital "RZD-Medicine" of the city of Yaroslavl", Yaroslavl, Russian Federation

Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib

Phase 2

Completed

Conditions: Pain Syndrome

Interventions: Drug: Etoricoxib

First Posted Date: 2020-09-25

Last Posted Date: 2022-02-14

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 144

Registration Number: NCT04565600

Locations: 🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China

Oral Huzhang Granules for Acute Gouty Arthritis

Phase 2

Conditions: Gouty Arthritis

Interventions: Drug: Huzhang granule
Drug: Etoricoxib
Drug: Etoricoxib Placebo
Drug: Huzhang granule Placebo

First Posted Date: 2020-07-08

Last Posted Date: 2020-07-08

Lead Sponsor: Shanghai Yueyang Integrated Medicine Hospital

Target Recruit Count: 267

Registration Number: NCT04462666

Etoricoxib vs Aceclofenac in the Treatment of Patients With Rheumatoid Arthritis

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Aceclofenac
Drug: Etoricoxib

First Posted Date: 2019-10-30

Last Posted Date: 2019-10-30

Lead Sponsor: Chung Shan Medical University

Target Recruit Count: 40

Registration Number: NCT04144101

Serum Creatinine Change / Renal Adverse Effect With Use of Non-steroidal Painkillers in Axial Spondyloarthritis Patients

Phase 4

Completed

Conditions: Axial Spondyloarthritis

Interventions: Drug: Indomethacin SR, 75 Mg Oral Capsule, Extended Release
Drug: Etoricoxib 60 mg
Drug: Indomethacin 25 Mg Oral Capsule
Drug: Etoricoxib 90 mg

First Posted Date: 2018-07-11

Last Posted Date: 2018-07-11

Lead Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Target Recruit Count: 64

Registration Number: NCT03582332

Pulse Shortwave Therapy in Cervical Osteoarthritis

Not Applicable

Completed

Conditions: Cervical Osteoarthritis

Interventions: Device: ActiPatch
Drug: Etoricoxib 60 mg

First Posted Date: 2018-06-01

Last Posted Date: 2019-08-30

Lead Sponsor: BioElectronics Corporation

Target Recruit Count: 180

Registration Number: NCT03542955

Locations: 🇱🇧
New Mazloum Hospital, Tripoli, Lebanon

Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablets

Not Applicable

Completed

Conditions: Healthy

Interventions: Drug: Etoricoxib 120Mg Film-coated Tablet
Drug: Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk)

First Posted Date: 2018-02-05

Last Posted Date: 2018-02-05

Lead Sponsor: Dexa Medica Group

Target Recruit Count: 26

Registration Number: NCT03422575

Locations: 🇮🇩
PT Equilab International, Jakarta, Indonesia

Rebound Pain After Operations for Distal Radius Fractures With a Volar Plate in Brachial Plexus Block

Phase 3

Completed

Conditions: Brachial Plexus Block
Pain, Postoperative

Interventions: Drug: NaCl (Control)
Drug: Dexamethasone
Drug: Paracetamol
Drug: EtoriCoxib
Drug: Oxycodone
Drug: Ropivacaine

First Posted Date: 2017-01-05

Last Posted Date: 2020-09-21

Lead Sponsor: Oslo University Hospital

Target Recruit Count: 53

Registration Number: NCT03011905

Locations: 🇳🇴
Oslo Universitetssykehus, Ullevaal, dept of anaesthesiology, legevakten, Oslo, Norway

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy